Who was Barbara Mitchell?
  1. prescription drug innovation
  2. prescription drug innovation

prescription drug innovation

Janvier 12, 2018 12:33PM

Under OHIP+, access to new or innovative drugs for rare disorders is limited
Dr. Nigel Rawson
Printer-friendly version

Insurance companies are the principal beneficiaries of Ontario’s new publicly-funded pharmacare program.

Étiquettes:
OHIP+, pharmacare, new prescription drugs, prescription drug innovation, rare disorders, patients, children, ontario, kathleen wynne